我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

己酮可可碱治疗慢性充血性心力衰竭患者的远期疗效(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2008年第1期
页码:
51-54
栏目:
临床研究
出版日期:
2008-01-20

文章信息/Info

Title:
Longterm effects of pentoxifylline in patients with congestive heart failure
作者:
赵培; 龚开政; 孙红光; 吕晓蕾; 王顺娣; 孙晓宁; 杨慧芳; 蔡萍; 凤以良; 张振刚
扬州大学第二临床医学院心血管内科，江苏 扬州 225001
Author(s):
ZHAO Pei;  GONG Kaizheng;  SUN Hongguang;  LV Xiaolei;  WANG Shundi;  SUN Xiaoning;  YANG Huifang;  CAI Ping;  FENG Yiliang;  ZHANG Zhengang
Department of Cardiology, 2nd Clinical School of Medical College, Yangzhou University, Yangzhou,Jiangsu 225001, China
关键词:
己酮可可碱; 心力衰竭; 充血性; 炎症介质; 细胞因子
Keywords:
pentoxifylline;  heart failure;  chronic;  inflammatory mediator;  cytokine
分类号:
R972
DOI:
-
文献标识码:
A
摘要:
目的 观察己酮可可碱（PTX）治疗慢性充血性心力衰竭（CHF）患者远期疗效。方法 81例CHF患者在常规抗心衰治疗基础上被随机分成PTX组（PTX 200 mg，每日3次，n=41）和安慰剂组（n=40），共治疗12个月。观察治疗前后血浆细胞因子水平、NYHA心功能分级、心脏结构和功能、生活质量、运动耐量的变化以及PTX治疗对再住院率和病死率的影响。结果 74例CHF患者完成随访。与安慰组比较，PTX可显著降低血浆中高敏C反应蛋白、肿瘤坏死因子-α和单核细胞趋化蛋白-1的水平（均P<0.05）。此外，PTX在降低左室舒张末内径［(56±9) mm vs (61±7) mm, P<0.05］、增加左室射血分数［(48±11)% vs (41±12)%, P<0.05］和降低再住院率（34％ vs 61％, P<0.05）等方面较安慰剂组更显著，但两组间病死率无显著差异。结论 在常规抗心衰治疗基础上加用PTX可进一步改善CHF患者的临床状态，降低再住院率。
Abstract:
AIM To evaluate the longterm effects of pentoxifylline (PTX) on patients with congestive heart failure (CHF). METHODS A total of 81 patients with CHF, on the basis of conventional therapy, were randomized to PTX (PTX 200mg 3 times daily, n=41) group or placebo group (n=40) with a 12month followup. The effects of PTX on the plasma levels of the inflammatory mediators, NYHA classification, cardiac structure and function, quality of life and exercise capacity, rehospitalization and mortality were determined. RESULTS The 12month followup was completed in 74 patients. The levels of high sensitivity C reactive protein (hsCRP), tumor necrosis factorα (TNFα), interleukin6 (IL6), monocyte chemoattractant peptide1 (MCP1), soluble intercellular adhesion molecule1 (sICAM1) and IL10 concentrations in CHF patients were significantly higher than those in the healthy control. Compared with those in the placebo group, the levels of hsCRP, TNFα, and MCP1 in PTX group significantly decreased after a 12month (all P<0.05). PTX treatment decreased left ventricular enddiastolic dimension ［(61±7) mm vs (56±9) mm, P<0.05］and rehospitalization (P<0.05), and increased left ventricular ejection fraction ［(41±12)% vs (48±11)%, P<0.05］, scores of life quality and 6minute walking distance (all P<0.05). But no significant difference in mortality was found between the two groups. CONCLUSION Conventional therapy plus pentoxifylline may further improve the clinical status and reduce rehospitalization in patients with CHF.

参考文献/References

［1］ Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview ［J］. Heart, 2004, 90(4): 464-470.

［2］ Sliwa K, Skudicky D, Candy G, et al . Randomized investigation of effects of pentoxifylline on left ventricular performance in idiopathic dilated cardiomyopathy ［J］. Lancet, 1998, 351 (9109): 1091-1093.

［3］ Silwa K, Woodiwiss A, Kone VN. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study ［J］. Circulation, 2004, 109(6): 750-755.

［4］ Hunt SA, Baker DW, Chin MH, et al . ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary ［J］. Circulation, 2001, 104(24): 2996-3007.

［5］ Bittner V, Weiner DH, Yusuf S, et al . Prediction of mortality and morbidity with a 6minute walk test in patients with left ventricular dysfunction. SOLVD Investigators ［J］. JAMA, 1993, 270(14): 1702-1707.

［6］ 龚开政，张振刚，朱宁，等．SF36在慢性心力衰竭患者中的信度和效度评价 ［J］．中国康复医学杂志，2004，19（3）：182-184．

［7］ Deswal A, Petersen NJ, Feldman AM, et al . Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vasnarinone trial(VEST) ［J］. Circulation, 2001, 103(16): 2055-2059.

［8］ Baumgarten G, Knuefermann P, Mann DL. Cytokines as emerging targets in the treatment of heart failure ［J］. Trends Cardiovasc Med, 2000, 10(5): 216-223.

［9］ Janssen SP, GayanRamirez G, Van den Bergh A, et al . Interleukin6 causes myocardial failure and skeletal muscle atrophy in rats ［J］. Circulation, 2005, 111(8): 996-1005.

［10］Sardo MA, Castaldo M, Cinquegrani M, et al . Effects of AT1 receptor antagonist losartan on sICAM1 and TNFalpha levels in uncomplicated hypertensive patients ［J］. Angiology, 2004, 55(2): 195-203.

［11］Valente EG, Vernet D, Ferrini MG, et al . Larginine and phosphodiesterate (PDE) inhibitors counteract fibrosis in the Peyronie′ fibrotic plaque and related fibroblast cultures ［J］. Nitirc Oxide, 2003, 9(4): 229-244.

［12］MensahBrown EP, Stosic Grujicic S, Maksimovic D, et al . Downregulation of apoptosis in the target tissue prevents lowdose streptozotocininduced autoimmune diabetes ［J］. Mol Immunol, 2002, 38(1213): 941-946.

备注/Memo

备注/Memo:
收稿日期：2007-03-28.基金项目: 江苏省卫生厅项目资助（H200356）通讯作者：张振刚，主任医师，教授，主要从事心血管疾病研究Email:zhzg@yacn.net 作者简介：赵培，医师，硕士生Email:bszhaop@126.com
更新日期/Last Update: